Results 71 to 80 of about 3,441 (189)

Subgingival Bacterial Microbiota Profile of People Living With HIV‐1 Under HAART: A Systematic Review

Special Care in Dentistry, Volume 45, Issue 6, November/December 2025.
ABSTRACT Objective This systematic review aimed to assess the available literature on the subgingival bacterial microbiota profiles of PLHIV undergoing HAART. Materials and Methods This research was conducted in accordance with the PRISMA guidelines.
Tatiana Pinheiro de Macedo, Cristiane Gonçalves, Lucio Souza Gonçalves, Priscila Pereira Pavan Vidal, Josué da Costa Lima‐Junior, Mario Vianna Vettore, Rodrigo Carvalho de Souza   +6 more
wiley   +1 more source

Long-lasting enfuvirtide carrier pentasaccharide conjugates with potent anti-human immunodeficiency virus type 1 activity [PDF]

, 2010
Enfuvirtide (also known as Fuzeon, T-20, or DP-178) is an antiretroviral fusion inhibitor which prevents human immunodeficiency virus type 1 (HIV-1) from entering host cells.
Mazinghien, Romain, Vincent, Loic, Romain Mazinghien, Gauchet, Cecile, Schols, Dominique, Heidi Bompais, Jérôme Lemoine, Huet, Thierry, Kerbarh, Olivier, Clayette, Pascal, Arnaud Salvador, Querolle, Olivier, Petitou, Maurice, Cécile Gauchet, Jan Balzarini, Bompais, Heidi, Thierry Huet, Olivier Querolle, Loïc Vincent, Maurice Petitou, Olivier Kerbarh, Dubreucq, Guy, Bruno Lucidi, Dominique Schols, Lucidi, Bruno, Balzarini, Jan, Pascal Clayette, Guy Dubreucq, Salvador, Arnaud, Lemoine, Jerome   +29 more
core   +1 more source

Use of new antiretroviral drugs and classes in Bahia, Brazil: a real life experience on salvage therapy of AIDS patients

Brazilian Journal of Infectious Diseases, 2015
Antiretroviral therapy has significantly evolved in the last decade, with an increasing number of new drugs and classes. Currently, even heavily experienced patients can be successfully treated with new regimens.
Carlos Brites, Isabella Nóbrega, Eduardo Martins Netto   +2 more
doaj   +1 more source

Monitoring of Foreign Drug Safety Information

Безопасность и риск фармакотерапии, 2019
Analysis of administrative decisions of foreign regulatory authorities on the recoil of medicines and/or the need for changes in the instructions for their medical use due to changes in the safety profile, conducted by experts of the Scientific Centre ...
Editorial article
doaj   +1 more source

Protein- and Peptide-Based Virus Inactivators: Inactivating Viruses Before Their Entry Into Cells

Frontiers in Microbiology, 2020
Infectious diseases caused by human immunodeficiency virus (HIV) and other highly pathogenic enveloped viruses, have threatened the global public health.
Xiaojie Su, Qian Wang, Yumei Wen, Shibo Jiang, Shibo Jiang, Lu Lu   +5 more
doaj   +1 more source

Viral susceptibility to aplaviroc and enfuvirtide in virus from participants with resistance to maraviroc. [PDF]

, 2018
Viral susceptibility to aplaviroc and enfuvirtide in virus from participants with resistance to maraviroc.
Charles Craig (52348), Wei Huang (36889), Mike Westby (2238055), Paul Simpson (528063), David L. Robertson (64202), Marilyn Lewis (199665), Jonathan Toma (6157130), Mike Mosley (6157133), Julie Mori (3389570), Roy Mansfield (6157136), Elna van der Ryst (6157139), Jeannette M. Whitcomb (161996)   +11 more
core   +1 more source

Development of Protein- and Peptide-Based HIV Entry Inhibitors Targeting gp120 or gp41

Viruses, 2019
Application of highly active antiretroviral drugs (ARDs) effectively reduces morbidity and mortality in HIV-infected individuals. However, the emergence of multiple drug-resistant strains has led to the increased failure of ARDs, thus calling for the ...
Jing Pu, Qian Wang, Wei Xu, Lu Lu, Shibo Jiang   +4 more
doaj   +1 more source

Fast pH‐Driven Solubilization Method of Realgar (As4S4) to Reduce the Toxicity of Arsenic [As(III)] for Medicinal Purposes

Advanced Science, Volume 12, Issue 29, August 7, 2025.
Arsenic trioxide transformed acute promyelocytic leukemia therapy and shows promise against HIV. A new method to solubilize the mineral realgar produces different arsenic species depleting the main arsenic target, nuclear PML protein, and retaining effects on leukemic and HIV reservoir cells, while minimizing off‐target damage.
Bojana Lucic, Douglas Santana Franciscato, Helton Pereira Nogueira, Lara Gallucci, Alceu Totti Silveira Junior, Asmaa Mohamed Ismail, Millie Robinson, Teresa Dallinger, Claudia Gutfleisch, Jochen Kurz, Maytê Toledo, Jessica Dias da Silva Ferraz, Mohammad Tarek, Danilo Dias, Ricardo Sobhie Diaz, Mahmoud ElHefnawi, Mattia Forcato, Hugo P Monteiro, Marina Lusic, Iart Luca Shytaj, Andrea Savarino   +20 more
wiley   +1 more source

Enfuvirtide administration in HIV-positive transgender patients with soft tissue augmentation: US evaluation. [PDF]

, 2010
Enfuvirtide is a large protein that should be injected subcutaneously to ensure an appropriate absorption. Here we report the case of a transgender HIV-positive patient receiving enfuvirtide with an individualized background regimen of antiretroviral ...
Gervasoni C., FERRAIOLI, GIOVANNA, Ferraris L, Galli M, FILICE, CARLO, Gabrielli E, Riva A   +6 more
core  

Enfuvirtide, an HIV-1 Fusion Inhibitor, for Drug-Resistant HIV Infection in North and South America [PDF]

, 2003
Background: The T-20 vs. Optimized Regimen Only Study 1 (TORO 1) was a randomized, open-label, phase 3 study of enfuvirtide (T-20), a human immunodeficiency virus type 1 (HIV-1) fusion inhibitor.
Delehanty, John, Walmsley, Sharon, Eron Jr., Joseph J., Salgo, Miklos, Drobnes, Claude, Piliero, Peter J., Kuritzkes, Daniel R., Donatacci, Lucille, Chung, Jain, Montaner, Julio S.G., DeMasi, Ralph, Trottier, Benoit, Cohen, Calvin, Henry, Keith, Lalezari, Jacob P., O'Hearn, Mary   +15 more
core   +2 more sources